Literature DB >> 26730865

Treatment of Idiopathic Pulmonary Fibrosis.

William G Carlos1, Mary E Strek2, Tisha S Wang3, Harin Patel4, Ganesh Raghu5, Kevin C Wilson6, Carey C Thomson4.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26730865     DOI： 10.1513/AnnalsATS.201510-713CME

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN： 2325-6621


× No keyword cloud information.
  4 in total

1.  Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model.

Authors:  P Comeglio; S Filippi; E Sarchielli; A Morelli; I Cellai; C Corno; A Pini; L Adorini; G B Vannelli; M Maggi; L Vignozzi
Journal:  J Endocrinol Invest       Date:  2018-06-19       Impact factor: 4.256

2.  The Clinical Efficacy of Pulmonary Hypertension-Specific Agents in Idiopathic Pulmonary Fibrosis: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.

Authors:  Jonghoo Lee; Jae Uk Song
Journal:  J Korean Med Sci       Date:  2020-03-02       Impact factor: 2.153

3.  The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis.

Authors:  Grace Hyun J Kim; Jonathan G Goldin; Wendy Hayes; Andrea Oh; Benjamin Soule; Shuyan Du
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 4.031

4.  Microscopic Polyangiitis with Pulmonary Fibrosis: An Often-Recognized Manifestation of the Disease.

Authors:  Liam M Clifford; Jamma Li; Christopher J Renaud; Suran L Fernando
Journal:  Case Rep Rheumatol       Date:  2019-12-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.